Navigation Links
Dave Anderson and William Thomsen Join SRI International's Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
Date:2/23/2011

MENLO PARK, Calif., Feb. 23, 2011 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that two new principal scientists, Dave Anderson, Ph.D., and William Thomsen, Ph.D., have joined its Center for Advanced Drug Research (CADRE) in Shenandoah Valley, Virginia.

Dr. Anderson will serve as principal scientist in CADRE's proteomics group. He has more than 20 years of experience applying mass spectrometry and proteomics methods to a variety of scientific problems. At SRI, he will apply those methods to set up biomarker analytics for specific disease areas and study host-pathogen interactions and pathogen drug resistance mechanisms.

Prior to joining SRI, Dr. Anderson was senior director of proteomics at Catalyst Biosciences and research fellow for proteomics and target discovery at Rigel Pharmaceuticals. Earlier, he headed the protein chemistry department at Khepri Pharmaceuticals and then at Arris Pharmaceutical following its acquisition of Khepri. In between his positions in the biotech industry, he was a research professor at the University of Oregon.

Dr. Anderson received his Ph.D. from the University of Oregon. He has authored more than 60 publications and holds 42 U.S. patents.

Dr. Thomsen will serve as principal scientist in CADRE's metabolic diseases group, where he will lead research pertaining to metabolic diseases.

He joins SRI with more than 25 years of experience in pharmaceutical drug discovery, with an emphasis on target validation, assay development, high throughput screening, and molecular pharmacology. He has experience with several classes of discovery targets, including G protein coupled receptors, within multiple therapeutic areas, including: disorders of the central nervous system; endocrine, metabolic, cardiovascular, and immunological diseases; and cancer. Most recently, he served as the director of molecular pharmacology at Arena Pharmaceuticals.

Dr. Thomsen received his Ph.D. from the University of Michigan and was a postdoctoral fellow at the University of Washington.

About SRI's Center for Advanced Drug Research (CADRE)

SRI established the Center for Advanced Drug Research (CADRE) to improve the productivity of the pharmaceutical industry, help our nation respond to biothreats, and develop life-saving treatments for rare and neglected diseases. CADRE's mission is to create new therapeutics, diagnostics, and vaccines for infectious and other diseases and for biodefense. CADRE combines and partners with SRI's well-established expertise in drug discovery, computational biology, and preclinical development with a new proteomics laboratory to develop these solutions.

About SRI's Biosciences Division

SRI's Biosciences division carries out basic research, drug discovery, and drug development, and provides contract (CRO) services. SRI has all of the resources necessary to take R&D from "Idea to IND"®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and commercial clients and partners advance many drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International  

Silicon Valley-based SRI International, a nonprofit research and development organization, performs sponsored R&D for governments, businesses, and foundations. SRI brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Commemorating its 65th anniversary in 2011, SRI is known for world-changing innovations in computing, health and pharmaceuticals, chemistry and materials, sensing, energy, education, national defense, and more.


'/>"/>
SOURCE SRI International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TransTech Medical Solutions Expands Offering to MD Anderson Cancer Center to Include Outsourced Medical Transcription and Editing Services
2. Statement of Ben Anderson, Esq., Regarding Denial of Wyeths En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
3. Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
4. Frank Phillips, Paul Anderson and Federico Girardi Join SI-BONEs Medical Advisory Board
5. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
6. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
7. Help is Here Express Arrives in Anderson, Seneca
8. HS-7 Document Regarding Research @ M. D. Anderson Orlando
9. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
10. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
11. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017 Mederi Therapeutics today announced the ... 2468 patients who received  Stretta Therapy  to treat ... Systematic Review and Meta-Analysis of Controlled and Prospective ... of Gastroesophageal Reflux Disease ", was published in ... , MD, head of the Esophageal and Swallowing ...
(Date:2/27/2017)... Feb. 27, 2017  International Biophysics Corporation, a global medical ... today announced a 34% revenue growth in 2016 when compared ... unit sales.  This growth was fueled by its AffloVest® sales ... to the expansion of its global sales of surgical product ... CEO, "As we enter our 25 th year in ...
(Date:2/27/2017)... 2017  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ... 37 th Annual Healthcare Conference on Monday, March ... Boston, MA. A live webcast of Infinity,s ... Infinity,s website at www.infi.com , and will be ... About Infinity,Infinity is an innovative biopharmaceutical company dedicated to ...
Breaking Medicine Technology:
(Date:2/27/2017)... Linda, Ca (PRWEB) , ... February 27, 2017 ... ... Life Sciences, provides an overview on laser diffraction analysis as a tool to ... its capabilities, significance and potential to obtain improved results and novel scientific findings. ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast ... in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the ... Mackenzie Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... an upgrade to the company's Yelp listing. Bay Area residents struggling from thinning ... as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit ...
(Date:2/26/2017)... ... 25, 2017 , ... The February 13, 2017, assassination of Kim Jong-nam, the ... agents and the deadly use of chemical weapons. Many questions exist about the effect ... doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical Institute, and ...
Breaking Medicine News(10 mins):